… On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day LEIDEN, the Netherlands, Feb. … said Daniel A. de Boer, Chief Executive Officer of ProQR. “Together with our partners at the Leiden Bio Science … Sariette Witte Investor Relations T: +1 213 261 8891 ir@proqr.com …
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025
Axiomer activity demonstrated across multiple preclinical in vitro
… ProQR Announces Results for the Fourth Quarter and Full Year … said Daniel A. de Boer, Chief Executive Officer of ProQR. “QR-110, our second development program targeting … for QR-313 is expected to start in 2018. ProQR’s inaugural R&D day provides key updates on drug pipeline: On March 14 th …
… ProQR Announces Results for the Fourth Quarter and Full Year … of 2017 and Business Update QR-110 for LCA 10 In April, ProQR’s QR-110 for Leber’s congenital amaurosis 10 (LCA 10) … Questionnaire-Revised Respiratory Symptom Score, or CFQ-R RSS) compared to placebo. A supportive trend was observed …
Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favora
Top-line results expected H1 2022
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan.
… ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology Key updates ProQR presents in vivo data in a relevant disease model, … The Netherlands, Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced that a …
… ProQR Announces Results for the Third Quarter of 2015 and … LEIDEN, The Netherlands, Nov. 23, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … studies," said Daniel de Boer, Chief Executive Officer of ProQR. “Our teams have taken a number of steps to accelerate …
… ProQR Provides Enrollment Update on QR-110 Clinical Trial and … and retinal structure in the second half of the year. ProQR to present two abstracts on programs for Fuchs … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We look forward to the clinical data for the QR-110 …
